Manchester Score for Prognosis in Small Cell Lung Cancer
ورودیهای بالینی بیمار
حداقل ۱۱۰ — حداکثر ۱۶۰ • واحد: mmol/L
حداقل ۱۰ — حداکثر ۴۰ • واحد: mmol/L
حداقل ۰ — حداکثر ۱۰۰ • واحد: points
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Good Prognosis0–1
- Medium Prognosis2–3
- Poor Prognosis4–6
The Manchester Score for Prognosis in Small Cell Lung Cancer calculator is designed for bedside predicting 2-year survival in patients with small cell lung cancer (SCLC) using six clinical and laboratory parameters in clinical practice. The resulting score directly guides clinician decision-making regarding determining appropriate.
Clinical Guidelines & Evidence
Predicts 2-year survival in patients with small cell lung cancer (SCLC) using six clinical and laboratory parameters. Stratifies patients into three prognostic groups (good, medium, poor) to guide treatment decisions and clinical management.
Clinical Indication
The Manchester Score for Prognosis in Small Cell Lung Cancer is indicated for bedside clinical practice to support Predicts 2-year survival in patients with small cell lung cancer (SCLC) using six clinical and laboratory parameters. Stratifies patients into three prognostic groups (good, medium, poor) to guide treatment decisions and clinical management.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with community-acquired pneumonia, COPD exacerbations, acute asthma, pulmonary embolism, or acute respiratory distress. Clinical application is indicated across Respiratory care units, emergency pulmonary triage, sleep clinics, and medical floors.
Limitations & Contraindications
Peripheral pulse oximetry loses reliability in hypoperfusion, severe vasoconstriction, methemoglobinemia, or carboxyhemoglobinemia.
Clinical Pearls & Action Plan
Synchronous evaluation of arterial blood gas (PaO2/FiO2), mechanics of breathing, and clinical trajectory guides respiratory failure management. Guideline pearl: 61 pre-treatment variables were initially evaluated through multiple regression analysis.
Manchester Score = LDH points + Sodium points + Alkaline Phosphatase points + Bicarbonate points + Disease Stage points + Karnofsky Performance Status points. LDH >ULN (1 point), Na <132 mmol/L (1 point), ALP >1.5x ULN (1 point), HCO3 <24 mmol/L (1 point), Extensive stage (1 point), KPS ≤50 (1 point). Total score 0-1 = Good prognosis, 2-3 = Medium prognosis, 4-6 = Poor prognosis.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| serum_ldh | string | Yes | Serum lactate dehydrogenase level relative to upper limit of normal. Elevated LDH reflects increased tumor burden and metabolic activity, indicating worse prognosis |
| serum_sodium | float | Yes | Serum sodium concentration in mmol/L. Hyponatremia (<132 mmol/L) often results from SIADH (syndrome of inappropriate antidiuretic hormone secretion) commonly associated with SCLC(mmol/L) |
| serum_alkaline_phosphatase | string | Yes | Serum alkaline phosphatase level relative to upper limit of normal. Elevated ALP (>1.5x normal) suggests liver or bone metastases, indicating extensive disease |
| serum_bicarbonate | float | Yes | Serum bicarbonate concentration in mmol/L. Low bicarbonate (<24 mmol/L) may indicate metabolic acidosis associated with advanced disease or organ dysfunction(mmol/L) |
| disease_stage | string | Yes | Small cell lung cancer staging. Limited stage: confined to one hemithorax including ipsilateral hilar and supraclavicular nodes. Extensive stage: disease beyond limited stage boundaries |
| karnofsky_performance_status | integer | Yes | Karnofsky Performance Status scale (0-100). Measures functional status and ability to carry out activities of daily living. Lower scores indicate worse functional status and prognosis(points) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–1 | Good Prognosis | Good prognostic group with best survival outcomes |
| 2–3 | Medium Prognosis | Intermediate prognostic group with moderate survival outcomes |
| 4–6 | Poor Prognosis | Poor prognostic group with worst survival outcomes |
Evidence-Based References (EBM)
- Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer. 1987 Jul 15;40(1):1-7. doi: 10.1002/ijc.2910400102.DOI: 10.1002/ijc.2910400102
- Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol. 1995 May;13(5):1221-30. doi: 10.1200/JCO.1995.13.5.1221.DOI: 10.1200/JCO.1995.13.5.1221
- Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol. 1990 Sep;8(9):1563-74. doi: 10.1200/JCO.1990.8.9.1563.DOI: 10.1200/JCO.1990.8.9.1563